Lin Elizabeth Yeu 4

What Happened

• Lin Elizabeth Yeu, Chief Medical Officer of Tarsus Pharmaceuticals, reported three open-market sales (code S) totaling 1,144 shares: 375 shares at $69.42 on 2026-03-17 ($26,033); 379 shares at $68.71 on 2026-03-18 ($26,041); and 390 shares at $67.00 on 2026-03-19 ($26,130). Aggregate proceeds were approximately $78,204. These were sales (dispositions), not purchases.

Key Details

• Transaction dates & prices:
  • 2026-03-17: 375 shares @ $69.42 = $26,033
  • 2026-03-18: 379 shares @ $68.71 = $26,041
  • 2026-03-19: 390 shares @ $67.00 = $26,130
• Total: 1,144 shares; ~$78,204 proceeds.
• Shares owned after the transactions: not specified in the provided filing.
• Filing date: Form 4 filed 2026-03-19 (covers trades dated 2026-03-17–03-19).
• Footnote: Sales were sell-to-cover transactions to satisfy tax withholding on RSU vesting and were mandated by the issuer (not discretionary by the insider).

Context

• "Sell-to-cover" means shares were sold specifically to cover tax withholding tied to RSU settlement; this is a routine administrative transaction and not necessarily an indicator of the insider's view of the company. Purchases typically convey stronger signals than mandatory sell-to-cover sales.